US 10,947,203 B2 · 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor

Abstract

In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles having a structure represented by a formula: which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims10

Dependent claims

A pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure represented by a formula:

wherein R1 is hydroxy, halogen, C1-C6 alkyl, C1-C6 alkoxy, or (C1-C6)OH;
wherein R2 is hydrogen, halogen, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 monohaloalkyl, C1-C6 polyhaloalkyl, —CO2H, —(C═O)H, —(C═O)-(C1-C6 alkyl), or (C═O)—O(C1-C6 alkyl);
wherein R3 is hydrogen, hydroxy, halogen, C1-C6 alkyl, C1-C6 alkoxy, or -(C1-C6)-OH;
wherein R5 is hydrogen, halogen, hydroxy, or C1-C3 alkyl;
wherein R6 is hydrogen, halogen, hydroxy, or C1-C3 alkyl;
and
wherein R7 is C1-C6 alkyl,
or a pharmaceutically acceptable salt thereof, provided that the compound is not:
and a pharmaceutically acceptable carrier.

6 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/679,007Filed 8 Nov 2019 · division

Priority

25 Mar 2016

Published

US 2020/0071281 A15 Mar 2020

Granted

16 Mar 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07D 249/06
1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles: with aryl radicals directly attached to ring atoms
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0095
Galenical forms not covered by A61K9/02 - A61K9/7023: drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets…
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Family

Application62/313,603Us provisional application · filed 25 Mar 2016

PCT/US2017/021949Parent of this division · filed 10 Mar 2017

US 2020/0071281 A1Pre-grant publication · published 5 Mar 2020

Application16/085,972Parent of this division

US 10,550,091 B2Parent of this division

US 2019/0077770 A1Published application

US 10,947,203 B2This patent

From the US filing history. Foreign family members aren’t listed.

1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor

Life of this patent

1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor

Life of this patent

Abstract

Claims10